In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent

Fanny Angelot-Delettre, Anne Roggy, Arthur E. Frankel, Baptiste Lamarthee, Estelle Seilles, Sabeha Biichle, Bernard Royer, Eric Deconinck, Eric K. Rowinsky, Christopher Brooks, Valerie Bardet, Blandine Benet, Hind Bennani, Zehaira Benseddik, Agathe Debliquis, Daniel Lusina, Mikael Roussel, Françoise Solly, Michel Ticchioni, Philippe Saas & 1 others Francine Garnache-Ottou

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of inter-leukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P

Original languageEnglish (US)
Pages (from-to)223-230
Number of pages8
JournalHaematologica
Volume100
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Interleukin-3 Receptors
Biological Factors
Dendritic Cells
Neoplasms
In Vitro Techniques
Cell Line
Cytotoxins
Standard of Care
Flow Cytometry
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent. / Angelot-Delettre, Fanny; Roggy, Anne; Frankel, Arthur E.; Lamarthee, Baptiste; Seilles, Estelle; Biichle, Sabeha; Royer, Bernard; Deconinck, Eric; Rowinsky, Eric K.; Brooks, Christopher; Bardet, Valerie; Benet, Blandine; Bennani, Hind; Benseddik, Zehaira; Debliquis, Agathe; Lusina, Daniel; Roussel, Mikael; Solly, Françoise; Ticchioni, Michel; Saas, Philippe; Garnache-Ottou, Francine.

In: Haematologica, Vol. 100, No. 2, 2015, p. 223-230.

Research output: Contribution to journalArticle

Angelot-Delettre, F, Roggy, A, Frankel, AE, Lamarthee, B, Seilles, E, Biichle, S, Royer, B, Deconinck, E, Rowinsky, EK, Brooks, C, Bardet, V, Benet, B, Bennani, H, Benseddik, Z, Debliquis, A, Lusina, D, Roussel, M, Solly, F, Ticchioni, M, Saas, P & Garnache-Ottou, F 2015, 'In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent', Haematologica, vol. 100, no. 2, pp. 223-230. https://doi.org/10.3324/haematol.2014.111740
Angelot-Delettre, Fanny ; Roggy, Anne ; Frankel, Arthur E. ; Lamarthee, Baptiste ; Seilles, Estelle ; Biichle, Sabeha ; Royer, Bernard ; Deconinck, Eric ; Rowinsky, Eric K. ; Brooks, Christopher ; Bardet, Valerie ; Benet, Blandine ; Bennani, Hind ; Benseddik, Zehaira ; Debliquis, Agathe ; Lusina, Daniel ; Roussel, Mikael ; Solly, Françoise ; Ticchioni, Michel ; Saas, Philippe ; Garnache-Ottou, Francine. / In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent. In: Haematologica. 2015 ; Vol. 100, No. 2. pp. 223-230.
@article{fbb315efd1e24106a2cff24649509e41,
title = "In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent",
abstract = "Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of inter-leukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P",
author = "Fanny Angelot-Delettre and Anne Roggy and Frankel, {Arthur E.} and Baptiste Lamarthee and Estelle Seilles and Sabeha Biichle and Bernard Royer and Eric Deconinck and Rowinsky, {Eric K.} and Christopher Brooks and Valerie Bardet and Blandine Benet and Hind Bennani and Zehaira Benseddik and Agathe Debliquis and Daniel Lusina and Mikael Roussel and Fran{\cc}oise Solly and Michel Ticchioni and Philippe Saas and Francine Garnache-Ottou",
year = "2015",
doi = "10.3324/haematol.2014.111740",
language = "English (US)",
volume = "100",
pages = "223--230",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

TY - JOUR

T1 - In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent

AU - Angelot-Delettre, Fanny

AU - Roggy, Anne

AU - Frankel, Arthur E.

AU - Lamarthee, Baptiste

AU - Seilles, Estelle

AU - Biichle, Sabeha

AU - Royer, Bernard

AU - Deconinck, Eric

AU - Rowinsky, Eric K.

AU - Brooks, Christopher

AU - Bardet, Valerie

AU - Benet, Blandine

AU - Bennani, Hind

AU - Benseddik, Zehaira

AU - Debliquis, Agathe

AU - Lusina, Daniel

AU - Roussel, Mikael

AU - Solly, Françoise

AU - Ticchioni, Michel

AU - Saas, Philippe

AU - Garnache-Ottou, Francine

PY - 2015

Y1 - 2015

N2 - Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of inter-leukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P

AB - Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of inter-leukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P

UR - http://www.scopus.com/inward/record.url?scp=84964299203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964299203&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.111740

DO - 10.3324/haematol.2014.111740

M3 - Article

VL - 100

SP - 223

EP - 230

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -